围受孕期孕酮使用与妊娠期高血压疾病:基于人群的队列研究
结果发现孕酮使用与任何新发妊娠期高血压疾病风险降低相关(aRR 0.81),主要因妊娠期高血压风险降低(aRR 0.60),而子痫前期风险无显著变化(aRR 0.97)。
要点
- 围受孕期孕酮使用与妊娠期高血压风险降低相关,子痫前期风险无显著改变。
- 在辅助生殖技术受孕人群中结果相似,妊娠期高血压风险仍降低。
- 该发现尚不足以改变临床实践,需进一步研究验证。
核心结论
- 围受孕期孕酮使用与妊娠期高血压风险显著降低相关,但与子痫前期风险无显著关联。
研究设计与样本
- 暴露组为围受孕期(孕前6周至孕早期结束)使用孕酮者,对照组为未使用孕酮者,采用逆概率加权回归调整控制混杂因素。
主要发现
- 5657例(1.5%)在围受孕期使用孕酮。
- 任何新发妊娠期高血压疾病风险降低:aRR 0.81(95%CI 0.67–0.98),aRD −1.72%(95%CI −3.21%至−0.24%)。
- 妊娠期高血压风险降低:aRR 0.60(95%CI 0.43–0.83),aRD −1.69%(95%CI −2.52%至−0.86%)。
- 子痫前期风险无显著变化:aRR 0.97(95%CI 0.75–1.25),aRD −0.13%(95%CI −1.49%至1.23%)。
- 辅助生殖技术受孕亚组中,妊娠期高血压风险降低:aRR 0.80(95%CI 0.67–0.95),aRD −1.02%(95%CI −1.73%至−0.30%);子痫前期风险无显著变化:aRR 0.96(95%CI 0.83–1.11),aRD −0.25%(95%CI −1.23%至0.72%)。
临床怎么用
- 围受孕期孕酮使用可能与妊娠期高血压风险降低相关,但证据尚不足以推荐用于预防妊娠期高血压疾病。
- 临床决策应结合个体情况,并考虑现有指南推荐。
局限性
- 研究为观察性设计,可能存在残余混杂。
- 结论外推需谨慎,尚需更多研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Objective To investigate whether periconceptual use of progesterone is associated with an altered risk of new-onset hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, or superimposed preeclampsia). Design Population-based cohort study using statewide pregnancy and birth data from Victoria, Australia, linked with hospital and medication prescribing data. Setting Victoria, Australia (2009–2020). Population Nulliparous women who gave birth between 2009 and 2020 in Victoria, Australia. Women with missing delivery dates, medicine dispensation dates, or who were exposed to progesterone in the second or third trimester were excluded. Methods We compared nulliparous women exposed to progesterone in the periconceptual period (6 weeks preconception until the end of the first trimester) with those not exposed to progesterone. Inverse probability-weighted regression adjustment was used to control for confounding factors and investigate the effect of progesterone on the risk of preeclampsia (including superimposed preeclampsia) and gestational hypertension. Main Outcome Measures Development of preeclampsia or gestational hypertension. Results Among 386 475 pregnancies, 5657 (1.5%) women used progesterone in the periconceptual period. Progesterone use was associated with a statistically significant reduction in the risk of any new onset hypertensive disorders of pregnancy (adjusted risk ratio [aRR] 0.81 [95% confidence interval [CI] 0.67, 0.98]; adjusted risk difference [aRD] −1.72% [95% CI −3.21%, −0.24%]). Investigating type of hypertension, we found progesterone use was associated with a 1.69% absolute reduced risk of gestational hypertension (aRR 0.60 [95% CI 0.43, 0.83]; aRD −1.69% [95% CI −2.52%, −0.86%]) but no significant change was observed for preeclampsia (aRR 0.97 [95% CI 0.75, 1.25]; aRD −0.13% [95% CI −1.49%, 1.23%]). Restricting our analyses to pregnancies conceived via assisted reproductive technology only, we found similar results, with a statistically significant reduction in the risk of gestational hypertension (aRR 0.80 [95% CI 0.67, 0.95]; aRD −1.02% [95% CI −1.73%, −0.30%]) but not preeclampsia (aRR 0.96 [95% CI 0.83, 1.11]; aRD −0.25% [95% CI −1.23%, 0.72%]). Conclusions Among 386 475 nulliparous women, we found periconceptual progesterone use to be associated with a statistically significant reduction in the risk of gestational hypertension, but not preeclampsia. However, these findings are unlikely to be clinic
引用
- BJOG:Periconceptual Progesterone Use and Hypertensive Disorders of Pregnancy: A Population‐Based Cohort Study
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。